Table 1.
Baseline demographic and clinical characteristics of the included patients
| Variables | Discontinuation of tofacitinib (n=56) |
Discontinuation of methotrexate (n=57) |
| Age (years) | 56.6 (14.1) | 60.1 (11.8) |
| Gender, n (% female) | 48 (85.7) | 47 (82.5) |
| Disease duration (month) | 96.6 (99.7) | 110.9 (103.3) |
| Steinbrocker’s classification, %, I/II/III/IV | 18/52/12/18 | 25/40/16/19 |
| Treatment history | ||
| Prior use of biologics | 40 (71.4%) | 36 (63.2%) |
| MTX use at baseline, n (%) | 56 (100.0) | 57 (100.0) |
| Dose, mg/week | 12.4 (3.5) | 11.4 (4.0) |
| Glucocorticoid use at baseline, n (%) | 6 (10.7) | 4 (7.0) |
| Dose, mg/day | 4.4 (1.0) | 5.0 (2.0) |
| Tofacitinib dose/day, n (%) | 5 mg; 2 (3.6), 10 mg; 54 (96.4) | 5 mg; 6 (10.5), 10 mg; 51 (89.5) |
| 28-Tender joint count | 8.4 (6.0) | 8.8 (5.8) |
| 28-Swollen joint count | 8.2 (4.7) | 7.0 (4.5) |
| PGA, VAS 0–100 mm | 55.6 (25.3) | 48.7 (22.6) |
| EGA, VAS 0–100 mm | 46.3 (21.8) | 44.0 (21.2) |
| DAS28-ESR | 5.5 (1.3) | 5.2 (1.2) |
| CDAI | 27.4 (12.2) | 25.5 (11.2) |
| HAQ-DI | 1.3 (0.8) | 1.2 (0.8) |
| CRP (mg/dL) | 2.1 (3.3) | 1.9 (3.1) |
| ESR (mm/hour) | 45.4 (32.6) | 39.0 (30.5) |
| Rheumatoid factor (U/mL) | 141.9 (168.9) | 173.1 (355.6) |
| Positive (%) | 50 (89.3) | 36 (63.2) |
| Anti-CCP antibody (U/mL) |
186.7 (291.9) | 179.1 (411.0) |
| Positive (%) | 49 (87.5) | 39 (68.4) |
| MMP-3 (ng/mL) | 264.4 (383.3) | 198.2 (269.8) |
Data reported as mean (SD).
CCP, cyclic citrullinated peptide; CDAI, Clinical Disease Activity Index; CRP, C reactive protein; DAS28, Disease Activity Score 28 Joint; EGA, Evaluator’s Global Assessment; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; MMP-3, matrix metalloproteinase-3; MTX, methotrexate; PGA, Patient’s Global Assessment.